News
Researchers identify a new prognostic biomarker of relapse in cutaneous squamous cell carcinoma and the mechanisms responsible for tumor progression
The study, which has been published in the scientific journal ‘Journal of Experimental & Clinical Cancer Research’, shows that the ITGAV protein allows a better stratification of patients and reveals new therapeutic avenues for this carcinoma.
IDIBELL’s scientific and technical services incorporate a new spatial transcriptomics and proteomics platform
The purchase of the equipment has been financed by the Carlos III Health Institute (IFEQ22 call).
A new genomic study analyzes antibiotic resistance in two species of pathogenic bacteria
The research carried out by IDIBELL and Bellvitge University Hospital has found a higher level of antibiotic resistance in parainfluenzae than H. influenzae.
Dr. Gabriela Abelenda receives a Juan Rodés postdoctoral scholarship for her research on respiratory infections
The grant will fund research on respiratory infections, the Antibiotic Use Optimization Program (PROA) incorporating a “One Health” perspective.
A study describes how insulinomas, a rare type of pancreatic beta cell tumour, form
The cause is a change in the epigenetic pattern of the beta cells of the pancreas, which overexpress oncogenes and genes related to insulin production, thus altering their functioning.
A study by IDIBELL and ICO proves the advantages of administering chemotherapy before surgery in stage II and III breast cancer
Neoadjuvant chemotherapy in breast cancer facilitates surgery and offers prognostic value. The 10-year survival rate is 84%, and 96% of patients who have a complete response to chemotherapy do not metastasize.
A new bioinformatics algorithm improves the genetic detection of Lynch and CMMRD syndromes
Researchers from IDIBELL and ICO have developed a bioinformatics algorithm that will improve the diagnosis of two cancer predisposition syndromes. This technique will speed up the diagnosis process and therapeutic decision-making in patients with suspected hereditary cancer.
Bellvitge Hospital incorporates voice-based artificial intelligence in the follow-up of patients with severe asthma
This is the first time that this technology has been applied to asthma in Spain. Some months ago, this IDIBELL and HUB group launched a mobile app for the follow-up of this disease.
Mutua Madrileña Foundation supports a Bellvitge project that will promote the clinical use of bioartificial kidneys
The study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.